Toronto, Ontario – (Newsfile Corp. – November 23, 2021) – LIVE Cannabis Inc (TSX: LIVE) (OTCQX: VVCIF) (“ALIVE“or the”Company“), a leading provider of medical cannabis products and patient services, and licensed under the Cannabis Law through its wholly owned subsidiaries, Canna Farms Limited (“Canna Farms”) and ABcann Medicinals Inc., today announced the launch of its new medicinal cannabis product formulation: high dose cannabidiol oil (CBD). ) under its Beacon Medical brand ™.
Beacon Medical dos 2: 100 High Dose CBD Oil is a distillate-based cannabis oil containing 100 mg of CBD and less than 2 mg of tetrahydrocannabinol (THC). The entire Beacon Medical ™ oil product family is made with a medium chain triglyceride (MCT) carrier oil of non-transgenic food grade, which makes the final product odorless and tasteless.
“With our commitment to the medical cannabis market, the VIVO team aspires to deliver premium cannabinoid-based medical products to our patients and Beacon Medical. CBD + | O has been launched in response to patient ideas that our team has picked up over time, “said Ray Laflamme, co-founder of Canna Farms and CEO of VIVO.” We recognize that many of our patients are looking for products that meet their individualized needs. and this latest addition to the Beacon Medical product family is an excellent choice of high-potency CBD for patients and will be available to patients, doctors and hospitals alike. “
Beacon CBD + | O [2:100] Extra strong CBD oil to help patients achieve their health goals
To see an enhanced version of this chart, visit:
https://orders.newsfilecorp.com/files/3063/104861_d6d7d616944e29cd_002full.jpg
VIVO simultaneously announced the release of a Pediatric compassionate care program to support caregivers and families who need medical cannabis to treat a variety of pediatric conditions. Eligible patients will receive substantial discounts on all Beacon Medical Can, Canna Farms ™, Fireside ™ and Lumina ™ CBD products.
VIVO stands firm in its patient-centered approach that ensures consistent choice, access, and supply for patients. Beacon Medical ™ products are available exclusively in select medical markets in Canada, Australia and Germany.
This recently released CBD Beacon Medical High Oil is available through the Canna Farms e-commerce medical market for Canadian medical clients. Patients who need assistance registering or placing orders can contact VIVO Customer Support at 1 (855) 882-0988 or care@vivocannabis.com.
About VIVO Cannabis ™
VIVO Cannabis ™ is recognized for its trusted premium cannabis products and services. It has production and sales licenses from Health Canada and operates world-class indoor and seasonal growing facilities. VIVO has a collection of medical, health and wellness brands, each targeting different customer segments, such as Canna Farms ™, Beacon Medical ™, Fireside ™ and Lumina. Harvest Medicine ™, VIVO’s scalable, patient-centered network of medical cannabis clinics, has served more than 150,000 patient visits. VIVO is looking for various product partnership and development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com.
For more information:
VIVO Investor Relations
+1 416-848-9839
ir@vivocannabis.com
Instagram: https://www.instagram.com/vivo_cannabis/
Facebook: https://www.facebook.com/vivocanna/
Twitter: https://twitter.com/vivo_cannabis
LinkedIn: https://www.linkedin.com/company/vivo-cannabis-inc/
Exemption from liability for forward-looking information
Some statements in this press release are forward-looking statements, which are statements that are not purely historical, including statements about VIVO’s beliefs, plans, expectations or intentions and its future management. These statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements. It cannot be guaranteed that any of the events provided for in the forward-looking statements will occur or, if so, what benefits the company will derive from them. Readers are asked to carefully consider these factors along with the most extensive risk factors included in the discussion and analysis of the most recent management of the company available at SEDAR, when evaluating the forward-looking statements contained in this press release and caution. that they do not unduly rely on these forward-looking statements, which are qualified in their entirety by these warning statements. The forward-looking statements in this press release are made on the date of this document and the company disclaims any intention or obligation to publicly update these forward-looking statements, whether as a result of new information, events or future results or otherwise, except as required by applicable securities laws.
To view the source version of this press release, visit https://www.newsfilecorp.com/release/104861
